Institut de Recerca Sant Pau - Centre CERCA
The Sant Pau Research Institute (IR Sant Pau), a health research institute (IIS) accredited by the Instituto de Salud Carlos III (ISCIII), continues its commitment to primary care research with the incorporation of the Dreta de l’Eixample Primary Care Team (EAP). This is a new member of the consortium, in addition to the EAP Sardenya, which has been part of IR Sant Pau since its foundation. Together, the two institutions provide healthcare coverage for a population of 74,207 people.
An international team of researchers has demonstrated that the tetravalent dengue vaccine Qdenga provides significant protection against the disease under real-world conditions during the major 2024 epidemic in São Paulo, Brazil. The study, published in the journal The Lancet Infectious Diseases and led by Dr. Otavio Ranzani, head of the DataHealth Lab group at the Sant Pau Research Institute (IR Sant Pau). Together with Dr. Julio Croda, Fiocruz, Brazil, provides the first evidence of the vaccine’s effectiveness following its approval.
Mariona’s Adventure has arrived at the Barcelona Zoo with resounding success. All the scheduled workshops were fully booked, and participants enjoyed a day of scientific discovery in a unique setting where biomedical research and environmental education came together. Held on Saturday, September 27, this mission marked a major highlight of the project’s second edition, as for the first time it moved beyond Tibidabo Amusement Park to reach another emblematic space in the city. The goal is to expand outreach settings and grow the community that accompanies Mariona in her scientific adventures.
This Saturday, September 27, a new mission of Mariona’s Adventure will take place, the educational and scientific outreach project designed to inspire vocations among children and adolescents, and break gender stereotypes that especially distance girls from the world of research.
On this occasion, the setting will be the Barcelona Zoo, a novelty that seeks to expand the spaces that host this project and reach new audiences in educational and accessible environments.
The approval of new antibody-based drugs for Alzheimer’s disease—lecanemab and donanemab—and of blood-based diagnostic tests marks the beginning of a new era in the diagnosis and treatment of this condition. However, without swift reforms in healthcare systems, public policies, and social attitudes, their full potential will not be realized, warn 40 leading Alzheimer’s experts in The Lancet Series on Alzheimer’s disease.
